Market revenue in 2023 | USD 4,996.2 million |
Market revenue in 2030 | USD 10,837.7 million |
Growth rate | 11.7% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Drug Eluting Stents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 22.77% in 2023. Horizon Databook has segmented the France drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
The competition in France’s drug device combination products market is intense due to the growing geriatric population, which is at a high risk of developing ARDS, making it one of the EU’s fastest-aging countries and a favorable market for drug-device combination products. As per a French national hospital database (Programme de Médicalisation des Systèmes d’Information (PMSI)), in 2021, the crude incidence of ARDS was 6.7 cases per 100,000 in people aged 18 to 40 and 51.9 cases per 100,000 in people aged 68 to 76.
Hence, due to the growing demand for efficient solutions to deal with the shifting demographic dynamics and an increasing number of surgical procedures, this demographic evolution has resulted in intense rivalry in the drug device combination products market in France.
Horizon Databook provides a detailed overview of country-level data and insights on the France drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into France drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account